The Federal Trade Commission has turned direct scrutiny toward telehealth marketing, and a July 2025 enforcement action against telemedicine provider NextMed shows exactly what draws it. The FTC alleged that the company advertised unsubstantiated weight-loss results, used fake testimonials and before-and-after photos from people who never used its services, manipulated online reviews, and made cancellation difficult for consumers enrolled in recurring GLP-1 membership programs. The matter closed with a final order in December 2025 and a $150,000 monetary judgment for consumer refunds. For telehealth companies advertising prescription-based care, the exposure runs through the same four categories: outcome claims, imagery, subscription terms, and endorsements.

The NextMed Enforcement Action

The Federal Trade Commission announced its case against Southern Health Solutions, Inc., doing business as Next Medical and NextMed, on July 14, 2025. The complaint alleged that NextMed advertised a monthly membership fee of $138 or $188 without disclosing that the price excluded the GLP-1 drug itself, required lab work, and the medical consultation needed for a prescription. The FTC also alleged NextMed claimed members lost 53 pounds and 23% of their body weight on average without records to support the claim, and that it published fake testimonials from hired individuals, employees, and family members, and used before-and-after photos of people who were not its customers. The final order, approved December 3, 2025, requires competent and reliable evidence before advertising results, disclosure of material connections with endorsers, informed consent before billing, and a simple cancellation process. NextMed agreed to pay $150,000 toward consumer redress.

The FTC's Substantiation Standard for Health Claims

The Federal Trade Commission's Health Products Compliance Guidance sets the standard for health-related advertising. A health claim needs competent and reliable scientific evidence: tests or studies conducted and evaluated objectively by qualified professionals in the relevant field and generally accepted as reliable within it. The guidance covers claims about the health benefits or safety of foods, dietary supplements, drugs, and other health-related products, whatever the marketing channel. A platform advertising a semaglutide or tirzepatide dispensing program carries the same substantiation burden as a supplement company advertising a comparable result, and that evidence needs to exist before the advertisement runs.

The FTC's order against NextMed reaches outcome claims, testimonials, and cancellation terms together, as a single advertising record.

Testimonials, Before-and-After Images, and Influencer Disclosure

The FTC's Endorsement Guides govern testimonials, reviews, and influencer content. An endorsement must reflect the endorser's honest opinion and actual experience with the product. Where a testimonial shows an atypical result, such as an above-average amount of weight lost in a short period, the advertiser must either support that the result is typical or clearly disclose what a typical result looks like. Any material connection between an endorser and the company, including payment or free product, needs clear and conspicuous disclosure where consumers will see it. A before-and-after photograph carries the same rule as a written testimonial: it has to belong to an actual patient and either represent a typical result or carry that same disclosure.

Subscription and Cancellation Terms

A membership structure draws separate scrutiny once billing becomes recurring. The FTC's order against NextMed required clear disclosure of the full membership cost before a consumer pays, informed consent before billing, and a cancellation process with no more obstacles than enrollment had. That order does not reach every seller: the Commission's general negative option rule imposed those same requirements industry-wide starting in 2024, but a federal appeals court vacated the 2024 amendments on procedural grounds, and the FTC reverted the rule in February 2026. In March 2026 the FTC opened a public comment period on whether to adopt new negative option rules along these lines, a sign the agency keeps watching this part of advertising.

State Attorneys General Add a Second Enforcement Track

State attorneys general enforce their own consumer protection statutes against telehealth advertising, independent of the FTC, and can reach conduct inside a single state that a federal matter does not capture. Our companion article on state attorney general investigations of telehealth companies covers how those inquiries open, what records they request, and how the process differs from an FTC matter. A telehealth company can face both tracks over the same campaign, and each track requires its own response.

Why Early Legal Counsel Is Critical

It is critical that telehealth companies promptly retain experienced healthcare defense counsel upon receiving a civil investigative demand, a state attorney general inquiry, or any other government request tied to advertising practices. Early legal intervention can protect the company's rights, shape how records and marketing materials are produced, help avoid inadvertent admissions in written responses, and preserve defenses that are harder to raise once a complaint or proposed order is already drafted. Delaying legal representation can significantly affect the outcome of a matter and expose the company to compliance obligations it did not negotiate.

How Health Law Alliance Can Help

Health Law Alliance represents telehealth companies, prescribers, and healthcare businesses facing Federal Trade Commission false and misleading advertising claims. Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience. If your telehealth platform is facing an advertising inquiry, or you want marketing reviewed before it draws one, contact our telehealth and telemedicine attorneys for a free, confidential consultation.